New research from Hunter College Professor Jill Bargonetti’s lab has identified two mutant versions of proteins in triple-negative breast cancers that are likely responsible for aiding growth in malignant tumors.
From these findings, researchers in Bargonetti’s lab identified two drugs that could, in combination, halt the protein mutations and lead to the first targeted therapy for triple-negative breast cancer.
